TAVR: The Need for a Pacemaker Is Associated with Mortality

Courtesy of Dr. Carlos Fava.

 

TAVR: The Need for a Pacemaker

After a transcatheter aortic valve replacement (TAVR), the incidence of permanent pacemaker (PPM) implantation ranges from 6% to 30% in different studies, depending on the valve type used. This is due to trauma, ischemia, haemorrhage, and atrioventricular node and infranodal tissue oedema, provoking ventricular dyssynchrony similar to that caused by complete left bundle branch block. The evolution of patients requiring permanent pacemaker after TAVR has not been fully studied.

 

This study included 9785 patients from 229 hospitals; 651 (6.65%) of these subjects received a permanent pacemaker.

 

Patients receiving a permanent pacemaker were more frequently men with a higher STS predicted risk of mortality score (7.3% vs. 6.7%; p = 0.004), who received aortic valvuloplasty less often and presented more conduction defects in the baseline echocardiogram.

 

During the procedure, patients requiring a permanent pacemaker received larger valves, with higher oversizing. Mean time between valve replacement and permanent pacemaker implantation was three days.

 

Self-expanding valves (CoreValve) required the implantation of permanent pacemakers more frequently than balloon-expandable valves (E. Sapiens). Extreme-risk or inoperable patients required a permanent pacemaker more frequently than high-risk patients. Hospital stays were longer for patients requiring a PPM.

 

At a year, the need for a permanent pacemaker was associated with an increase in mortality (24.1% vs. 19.6%; hazard ratio [HR]: 1.31; 95% confidence interval [CI]: 1.09 to 1.58) and an increase in a composite of mortality and heart failure (37.3% vs. 28.5%; HR: 1.33; 95% CI: 1.13 to 1.56).

 

The following were predictors of the need for permanent pacemaker implantation after TAVR at 30 days:

  • age;
  • prior conduction defect;
  • aortic valve area ≤0.75 cm2;
  • use of self-expanding valves.

 

Conclusion

The need for a pacemaker is a common complication following TAVR, and it is associated with higher mortality and hospitalization due to heart failure at one year.

 

Editorial

Prior studies argued that permanent pacemaker implantation did not affect outcomes. This study, however, proves the opposite: it is associated to a hard event, mortality, and a higher need for hospitalization due to heart failure. This also increases healthcare costs.

 

The upcoming challenge lies in the development of devices that lower the need for a permanent pacemaker while maintaining or improving current performance.

 

Courtesy of Dr. Carlos Fava. Buenos Aires Favaloro Foundation, Argentina.

 

Original title: Incidence, Predictors, and Outcomes of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement. Analysis from the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry.

Reference: Opeyemi O. FadaHunsi, et al. J Am Coll Cardiol Intv 2016;9:2189-99.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....